{"transactions":[{"id":2642,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"officer":true,"officer_title":"U.S. CCO & Country Gen Manager"}}],"security":"Restricted Share Units","published_at":"2026-09-03T20:36:38.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one Issuer American Depositary Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted share units (\"RSUs\") vest in four equal annual installments commencing on September 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted share units (\"RSUs\") vest in four equal annual installments commencing on September 1, 2026."}],"balance_after":60000,"derivative":{"underlying":"American Depositary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001730463-26-000131","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907199/000173046326000131/form4.xml","form_type":"4"}},{"id":2641,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"officer":true,"officer_title":"U.S. CCO & Country Gen Manager"}}],"security":"American Depositary Shares","published_at":"2026-09-03T20:36:38.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":6713,"price":2.336,"value":15681.568,"ownership":{"direct":true},"balance_after":13287,"source":{"system":"sec-edgar","filing":"0001730463-26-000131","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907199/000173046326000131/form4.xml","form_type":"4"}},{"id":2640,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"officer":true,"officer_title":"U.S. CCO & Country Gen Manager"}}],"security":"American Depositary Shares","published_at":"2026-09-03T20:36:38.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":2.35,"value":47000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001730463-26-000131","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907199/000173046326000131/form4.xml","form_type":"4"}},{"id":1254990,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:32:35.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015742","document":"tm257186-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015742/tm257186-3_4seq1.xml","form_type":"4"}},{"id":1254989,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:32:35.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015742","document":"tm257186-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925015742/tm257186-3_4seq1.xml","form_type":"4"}},{"id":1302289,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:18:53.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":12991,"price":0.5748,"value":7467.2268,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 25% of the remaining balance of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 92,652 ADSs and RSU-style options and other options covering an aggregate of 6,779,928 ordinary shares of the Issuer."}],"balance_after":18421,"source":{"system":"sec-edgar","filing":"0001104659-25-003774","document":"tm253441-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925003774/tm253441-4_4seq1.xml","form_type":"4"}},{"id":1474580,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-18T21:00:13.000Z","date":"2024-06-18","kind":"sale","planned":false,"acquired":false,"shares":24531,"price":0.93,"value":22813.83,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately one third of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,359 ADSs and RSU-style options and other options covering an aggregate of 6,968,400 ordinary shares of the Issuer."}],"balance_after":38293,"source":{"system":"sec-edgar","filing":"0001104659-24-072874","document":"tm2417532-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924072874/tm2417532-1_4seq1.xml","form_type":"4"}},{"id":1571905,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-03-18T21:00:12.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":1130832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 376,944 Ordinary Shares on June 18, 2024 and will be exercisable as to the remainder in installments of 188,472 Ordinary Shares on January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1130832,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1130832},"source":{"system":"sec-edgar","filing":"0001104659-24-035619","document":"tm249079d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924035619/tm249079d1_4seq1.xml","form_type":"4"}},{"id":1571904,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-03-18T21:00:12.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":5088864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.19 based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,679,325 Ordinary Shares on March 18, 2024 and will be exercisable as to the remainder in monthly installments of 94,704 Ordinary Shares on the last day of each month from April 18, 2024 through February 18, 2027 and 94,899 Ordinary Shares on March 18, 2027."}],"balance_after":5088864,"derivative":{"exercise_price":0.25,"expiration_date":"2034-03-18","underlying":"Ordinary Shares","underlying_shares":5088864},"source":{"system":"sec-edgar","filing":"0001104659-24-035619","document":"tm249079d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465924035619/tm249079d1_4seq1.xml","form_type":"4"}},{"id":1836445,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:00:20.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":273000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":273000,"derivative":{"exercise_price":3.24,"expiration_date":"2033-07-03","underlying":"Common Stock","underlying_shares":273000},"source":{"system":"sec-edgar","filing":"0001209191-23-041171","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123041171/doc4.xml","form_type":"4"}},{"id":1836444,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-07-05T21:00:20.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":147000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":147000,"source":{"system":"sec-edgar","filing":"0001209191-23-041171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123041171/doc4.xml","form_type":"4"}},{"id":2039881,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-02-01T02:02:17.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":11890,"price":1.8696,"value":22229.544,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.85 to $1.895, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 34,824 ADSs and RSU-style options and other options covering an aggregate of 5,845,530 ordinary shares of the Issuer."}],"balance_after":19535,"source":{"system":"sec-edgar","filing":"0001104659-23-008858","document":"tm231655-21_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923008858/tm231655-21_4seq1.xml","form_type":"4"}},{"id":2053510,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:02:27.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":181560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":181560,"derivative":{"exercise_price":0.0012,"exercise_date":"2024-01-17","expiration_date":"2025-03-15","underlying":"Ordinary Shares","underlying_shares":181560},"source":{"system":"sec-edgar","filing":"0001104659-23-004370","document":"tm231655-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004370/tm231655-10_4seq1.xml","form_type":"4"}},{"id":2053509,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:02:27.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":314256,"derivative":{"exercise_price":0.0012,"underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-23-004370","document":"tm231655-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004370/tm231655-10_4seq1.xml","form_type":"4"}},{"id":2053508,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:02:27.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027."}],"balance_after":1407072,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-23-004370","document":"tm231655-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923004370/tm231655-10_4seq1.xml","form_type":"4"}},{"id":2198817,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-08-02T01:00:27.000Z","date":"2022-08-01","kind":"sale","acquired":false,"shares":21040,"price":1.7735,"value":37314.44,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,131,192 ordinary shares of the Issuer."}],"balance_after":34824,"source":{"system":"sec-edgar","filing":"0001104659-22-084893","document":"tm2222258d1_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922084893/tm2222258d1_4seq.xml","form_type":"4"}},{"id":2420844,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-02-01T02:05:29.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":335184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":335184,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-07-31","expiration_date":"2023-03-15","underlying":"Ordinary Shares","underlying_shares":335184},"source":{"system":"sec-edgar","filing":"0001104659-22-009932","document":"tm221700-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922009932/tm221700-20_4seq1.xml","form_type":"4"}},{"id":2420843,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-02-01T02:05:29.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":754200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 188,550 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in annual installments of 188,550 Ordinary Shares on the thirty-first of each January from January 31, 2024 through January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":754200,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":754200},"source":{"system":"sec-edgar","filing":"0001104659-22-009932","document":"tm221700-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922009932/tm221700-20_4seq1.xml","form_type":"4"}},{"id":2420842,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":1934,"kind":"person","name":"Piccina Cintia","position":1,"cik":"0001907199","reported_name":"Piccina Cintia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-02-01T02:05:29.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":3376992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.33 based on an exchange rate of U.S.$1.34145 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 844,248 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in monthly installments of 70,350 Ordinary Shares on the last day of each month from February 28, 2023 through December 31, 2025 and 70,494 Ordinary Shares on January 31, 2026."}],"balance_after":3376992,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-31","underlying":"Ordinary Shares","underlying_shares":3376992},"source":{"system":"sec-edgar","filing":"0001104659-22-009932","document":"tm221700-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465922009932/tm221700-20_4seq1.xml","form_type":"4"}}]}